JSPR (Jasper Therapeutics) Shareholder Yield % : 5.80% (As of Mar. 2026)


JSPR Jasper Therapeutics Inc JSPR
24 GF Score
Price $0.43
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics Shareholder Yield %?

Jasper Therapeutics JSPR -5.19% 24 Shareholder Yield % is 5.80% as of Mar. 2026. GuruFocus rates JSPR with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 1,300 Biotechnology companies, Jasper Therapeutics ranks better than 91.15% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Jasper Therapeutics's Shareholder Yield % was 5.80%.


Jasper Therapeutics  (NAS:JSPR) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Jasper Therapeutics Shareholder Yield % Related Terms


Jasper Therapeutics Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Jasper Therapeutics's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jasper Therapeutics Shareholder Yield % Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial 0.00 -4.97 -114.37 -14.40 -65.78

Jasper Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 0.57 0.55 -65.78 2.99

JSPR vs CVKD, BRTX, APRE: Shareholder Yield % Comparison

For the Biotechnology subindustry, Jasper Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jasper Therapeutics Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's Shareholder Yield % falls into.


JSPR
24GF Score
Jasper Therapeutics Inc JSPR
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jasper Therapeutics Shareholder Yield % Calculation

Jasper Therapeutics's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+2.99 %
=2.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 5.80% mean?
Jasper Therapeutics (JSPR) has a Shareholder Yield % of 5.80% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Jasper Therapeutics and its competitors. According to the industry distribution chart, Jasper Therapeutics ranks #115 out of 1300 companies in the Biotechnology industry, placing it in the top 8.8%.
Is Jasper Therapeutics' Shareholder Yield % too high?
Jasper Therapeutics' current Shareholder Yield % is 5.80%. Based on the distribution chart, Jasper Therapeutics ranks #115 out of 1300 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jasper Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' Shareholder Yield % compare to CVKD and BRTX?
According to the Biotechnology industry distribution chart, Jasper Therapeutics ranks #115 out of 1300 companies for Shareholder Yield %. This places Jasper Therapeutics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Jasper Therapeutics and its competitors. Jasper Therapeutics's current Shareholder Yield % is 5.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current Shareholder Yield % of 5.80%. The current Shareholder Yield % is 5.80%. Jasper Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current Shareholder Yield % is 5.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
24GF Score

Get the complete analysis for JSPR

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price